The data is incremental and consistent with previously announced December 2025 topline results. No new regulatory catalyst or financial update — monitor for FDA meeting outcomes and Phase 3 initiation plans as the next value drivers.
Price Chart
Executive Summary
Palvella Therapeutics announced new Phase 2 TOIVA trial data for QTORIN rapamycin in cutaneous venous malformations, presented at the SID annual meeting. The data showed 100% of patients with baseline bleeding achieved statistically significant improvement on the cVM-IGA Bleeding scale at Week 12 (+2.5 points, p=0.003). This is a clinical-stage biotech update with no financial figures or regulatory milestones — the filing is a routine data readout disclosure.
Key Facts
- Phase 2 TOIVA trial data presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
- 100% of patients with bleeding at baseline (n=4) showed statistically significant improvement on cVM-IGA Bleeding at Week 12 (+2.5 point improvement; p=0.003)
- 100% of patients with bleeding at baseline reported being satisfied or very satisfied with QTORIN rapamycin on the Treatment Satisfaction Questionnaire for Medication at Week 12
- QTORIN rapamycin has potential to become first FDA-approved therapy for an estimated >75,000 individuals with cutaneous venous malformations in the U.S.
- TOIVA is a single-arm, open-label, baseline-controlled Phase 2 trial with 12-week efficacy evaluation and 12-week extension period
Financial Impact
No financial figures disclosed in the filing. Clinical-stage company with no approved products or reported revenue.
Risk Factors
- Phase 2 data from a single-arm, open-label trial with only 4 patients evaluable for the bleeding endpoint — limited statistical power
- QTORIN rapamycin is investigational and not yet FDA-approved for any indication
- Clinical-stage biotech with no approved products or revenue — dependent on future capital raises
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-225317 |
| Document: pvla-ex99_1.htm | 0001193125-26-225317 |
| Document: 0001193125-26-225317-index-headers.html | 0001193125-26-225317 |
| Document: 0001193125-26-225317-index.html | 0001193125-26-225317 |
| Document: 0001193125-26-225317.txt | 0001193125-26-225317 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 144 | $155.47 $132.47 | ▼ −14.79% | ▼ −13.61% | $132.47 (−14.79%) |
Aug 9, 2026 7w ago | Institutional Cluster | $152.22 $157.00 | ▲ +3.14% | ▲ +4.05% | $132.47 (−12.97%) |
Aug 4, 2026 8w ago | 8-K | $151.99 $150.55 | ▼ −0.95% | ▲ +0.29% | $132.47 (−12.84%) |
Jul 30, 2026 9w ago | Press Release | $150.19 $150.33 | ▲ +0.09% | ▼ −3.87% | $132.47 (−11.80%) |
Jul 28, 2026 9w ago | Press Release | $142.84 $148.24 | ▲ +3.78% | ▲ +0.40% | $132.47 (−7.26%) |
Jun 30, 2026 13w ago | 8-K | $152.82 $141.77 | ▼ −7.23% | ▼ −6.20% | $132.47 (−13.32%) |
Jun 22, 2026 14w ago | Press Release | $118.84 $157.24 | ▲ +32.31% | ▲ +32.46% | $132.47 (+11.47%) |
Jun 16, 2026 15w ago | 8-K | $110.12 $149.68 | ▲ +35.92% | ▲ +35.72% | $132.47 (+20.30%) |
Jun 11, 2026 16w ago | Institutional Cluster | $106.38 $151.04 | ▲ +41.98% | ▲ +40.09% | $132.47 (+24.53%) |
May 15, 2026 20w ago | 8-K | $114.24 $116.51 | ▲ +1.99% | ▼ −0.13% | $132.47 (+15.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access